Aleksandrs Zhavoronkov

Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Compass Asset Management SA is a private asset management firm based in Lugano, Switzerland. Founded in 1998, their clients are both private and institutional investors. They manage a number of Luxembourg-domiciled funds.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Sheba Medical Center is a hospital engaging in medical science and biotechnical innovation. Its services include emergency room services, cancer treatment, psychiatry, and hematological examination. The company was founded on June 21, 1948 and is headquartered in Ramat Gan, Israel.

Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy.

Hakluyt & Co. Ltd. is a strategic advisory firm founded in 1997. The private company is based in London, UK and has subsidiaries in the United Kingdom and the United States. The British company supports corporations and investors in identifying opportunities and risks facing their businesses.

Sintetica SA operates as a pharmaceutical company that provides injectable anaesthetics and analgesics. The company was founded in 1921 and is headquartered in Mendrisio, Swizerland.

CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Novigenix SA develops molecular diagnostics for cancer. The firm specializes in new generation liquid biopsy tests for early detection of cancer and precision medicine. The company was founded by Sahar Hosseinian in 2014 and is headquartered in Epalinges, Switzerland.

Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Antengene Corporation Co., Ltd. operates as a holding company. It engages in clinical development of drug candidates. The company was founded on June 15, 2016 and is headquartered in Shanghai, China.

Iotex engages in the provision of auto-scalable and privacy-centric blockchain platform for the Internet of Things. Its development includes a root chain/subchains architecture for heterogeneous computing, Roll-DPoS consensus mechanism for high scalability, and lightweight privacy-preserving techniques, The company was founded by Raullen Chai, Qevan Guo, andJing Sun in 2017 and is headquartered in Menlo Park, CA.

Intelligencia, Inc. develops artificial intelligence to de-risk clinical development. The firm offers data science solutions. The company was founded by Dimitrios Skaltsas and Vangelis Vergetis and is headquartered in New York, NY.

Part of Wuxi Biologics (Cayman), Inc., WuXi Biologics Germany GmbH is a company that engages in the development and manufacturing of biologics. The company is based in Leverkusen, Germany. The CEOs of the company are Zhisheng Chen, Jian Dong, Ming Zi Chen.

Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm).

SIA Longenesis promotes collaboration between biomedical institutions, patient organizations, and research partners. The company is based in Riga, Latvia and has subsidiaries in Hong Kong. The Latvian company identifies biomedical data from metadata files, onboards population cohorts, and engages new patients in research. The company was founded by Garri Zmudze.

PsyMed Ventures Management LLC (PsyMed Ventures) is a venture capital firm founded in 2020 by Dina Burkitbayeva and Matias Serebinsky. The firm is headquartered in Tahoma, California.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

Fusix Biotech GmbH is a private company located in Germany that aims to deliver breakthrough cancer immunotherapies utilizing a unique "fusogenic" mechanism of action to directly kill tumor cells, heat up the tumor microenvironment, and mediate systemic immune effects to target tumor cells throughout the body. The German company is still part of the Klinikum rechts der Isar of the Technical University Munich and is currently planning to spin-out in 2022. The Fusix technology offers a unique mechanism of action that will revolutionize immune oncology in solid cancers by converting the tumor microenvironment from an immune suppressed “cold” tumor into an immune-sensitized “hot” tumor infiltrated with immunotherapeutics.

Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999.